A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer

Arndt Vogel· @ArndtVogel · X·2026-10-24 16:45· 21 小时前评分70

正文 · 原文

A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer
#ESMO26 #ESMOAmbassadors
👉 ORR: 18 vs 5.3%
👉 mPFS: 4.7 vs 2.6 mo
👉 mOS: 8.9 vs 9.4 mo
🧐Active drug, but no OS benefit in 2nd line, could be explored in 1L
@myESMO @ASCO

92 浏览 · 4 赞 · 4 转发 · 0 回复

会议摘要

2878RO按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study

https://esmocongress.esmo.org

543RO按 Rapid oral: Breast cancer, early stage 对上

DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (

https://esmocongress.esmo.org

LBA37按 Proffered paper: Gynaecological cancers 对上

Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud

https://esmocongress.esmo.org

来源：Arndt Vogel · x.com